Former Chief Financial Officer and Principal Financial Officer · ROCKET PHARMACEUTICALS, INC. (RCKT)

Carlos Garcia-Parada

A named executive officer of ROCKET PHARMACEUTICALS in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,333,141

Salary $103,012Stock awards $330,000

FY2021: $5,693,840

7th of 7 named executive officers at Rocket Pharmaceuticals by FY2022 total.

7 named officers on file for ROCKET PHARMACEUTICALS, FY2022

Carlos Garcia-Parada’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • RCKT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ROCKET PHARMACEUTICALS’s whole pay program stands against its peers

  • ROCKET PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RCKT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A).

Free

Get Carlos Garcia-Parada’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Carlos Garcia-Parada compensation by year

ROCKET PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held
In US dollars, as ROCKET PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$410,000$103,012
Bonus$132,840$0
Stock awards$0$330,000
Option awards$5,139,400$670,000
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$11,600$230,129
Total$5,693,840$1,333,141

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ROCKET PHARMACEUTICALS, INC. DEF 14A filed April 28, 2023, accession 0001140361-23-021702, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ROCKET PHARMACEUTICALS, INC. filed document, accession 0001140361-23-021702. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

$5.7M
$1.3M
FY21
FY22
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option125,000—$56.49
Option40,000—$35.60

Per the Outstanding Equity Awards at Fiscal Year-End table in ROCKET PHARMACEUTICALS, INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

ROCKET PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Gaurav ShahChief Executive Officer$6,553,203
Kinnari PatelPresident and Chief Operating Officer$4,516,885
Mayo PujolsChief Technical Officer, Executive Vice President$3,149,702
Raj PrabhakarChief Business Officer, Senior Vice President$2,819,120
Jonathan SchwartzChief Medical and Gene Therapy Officer$2,532,457
John MilitelloPrincipal Accounting Officer and Interim Principal Financial Officer, Vice President$1,751,386
Carlos Garcia-Parada · this pageFormer Chief Financial Officer and Principal Financial Officer$1,333,141

The full ROCKET PHARMACEUTICALS compensation record

free company brief

This page is one person within ROCKET PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ROCKET PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ROCKET PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Carlos Garcia-Parada's compensation dossier · One-time report. No refunds.